SynchronyGamma: A Music-Based Intervention for Alzheimer's and Mild Cognitive Impairment

SynchronyGamma：针对阿尔茨海默病和轻度认知障碍的基于音乐的干预措施

• 批准号: 10484478
• 负责人: Edward W Large
• 金额: $ 44.97万
• 依托单位: OSCILLOSCAPE, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10484478
• 关键词: Adoption; Adult; Affect; Age-associated memory impairment; Aging; Algorithms; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer' s disease patient; Alzheimer' s disease therapy; American; Amyloid beta-Protein; Auditory; Behavior; Behavior Therapy; Behavioral Symptoms; Brain; Caregivers; Caring; Clinical; Cognition; Collaborations; Communities; Computer Models; Conduct Clinical Trials; Data; Devices; Disease; Early Intervention; Elderly; Electroencephalography; Executive Dysfunction; Feasibility Studies; Frequencies; Functional disorder; Funding; Goals; Human; Impaired cognition; Independent Living; Individual; Institutional Review Boards; Intervention; Interview; Lead; Learning; Legal patent; Light; Lighting; Longitudinal Studies; Measures; Memory; Memory Loss; Mental Depression; Modeling; Music; Neurodegenerative Disorders; Neurologist; Neurons; Neuropsychology; Neurosciences; Outcome; Outcome Measure; Pain; Participant; Patient Self-Report; Patients; Periodicity; Pharmacology; Phase; Photic Stimulation; Population; Process; Protocols documentation; Public Health; Research; Retirement; Rewards; Self-Help Devices; Senile Plaques; Sensory; Short-Term Memory; Small Business Innovation Research Grant; Structure; System; Technology; Testing; Time; United States National Institutes of Health; Universities; Visual; Work; base; cognitive ability; cognitive neuroscience; cost; digital health; experience; feasibility testing; improved; innovation; instrument; medical schools; mild cognitive impairment; mouse model; neural network; novel; novel therapeutics; patient population; preservation; prototype; relating to nervous system; response; secondary outcome; success; targeted biomarker; tool; usability

Project Summary/Abstract In this proposal, Oscilloscape, LLC seeks NIH-SBIR funding to conduct usability and feasibility studies on an innovative music-based digital health device that delivers non-invasive music and Gamma (30-80 Hz) brain stimulation to help aging adults with Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI). The digital health device, herein referred to as “SynchronyGamma,” is based on patented neural network technology that models the dynamics of rhythmic brain activity. We previously used this neural network technology to develop a scalable, low-cost LED-light controller, called Synchrony™, that creates colorful lighting effects that synchronize to the beat of music. Synchrony™ is currently marketed for music lighting, but its core algorithm has clinical potential, because it aims to stimulate healthy brain rhythms via the process of neural entrainment. In clinical populations who have disruptions in brain rhythms, e.g., patients with AD & MCI, we hypothesize that this technology can effectively restore normal brain activity important for learning, memory, and cognition. Key outcomes of this project are IRB-approved studies that 1) assess the usability of SynchronyGamma in independent living facilities, and 2) assess the feasibility of SynchronyGamma as a brain stimulation tool by studying the effects of SynchronyGamma on brain activity and cognitive abilities in a longitudinal intervention in older adults with MCI or AD. SynchronyGamma has potential to help age-related cognitive impairments by creating a music-based, digital health device that delivers Gamma stimulation via music and lights. Neurodegenerative disorders are a rapidly growing public-health concern, with AD alone projected to affect 13.8 million Americans in 2050. AD patients undergo gradual cognitive decline, with MCI being an early stage of the disorder. During this progression, patients experience multiple pain-points, including memory loss, executive function deficits, and depression. Early intervention in the MCI stage may reduce or even reverse cognitive decline. While pharmacological interventions for AD have primarily targeted biomarkers such as beta- amyloid (Aβ) plaques, these strategies have shown limited success in improving clinical outcomes. Thus, there is an urgent clinical need to develop novel therapies for AD and MCI. Recent findings that relate Gamma neural entrainment to Aβ offer an exciting avenue towards non-invasive sensory interventions. Our objective is to validate SynchronyGamma as an effective music-based therapy for restoring depleted brain activity, thus preserving and improving memory and cognition in patients with AD and MCI.

项目概要/摘要 在此提案中，Oscilloscape, LLC 寻求 NIH-SBIR 资助以开展可用性和可行性研究 研究基于音乐的创新数字健康设备，该设备可提供非侵入性音乐和 伽玛 (30-80 Hz) 大脑刺激可帮助患有阿尔茨海默病 (AD) 的老年人和 轻度认知障碍 (MCI) 数字健康设备，本文称为 “SynchronyGamma”基于对动力学进行建模的专利神经网络技术 我们之前使用这种神经网络技术开发了一种有节奏的大脑活动。 可扩展、低成本的 LED 灯控制器，称为 Synchrony™，可创造多彩的灯光效果 与音乐节拍同步的 Synchrony™ 目前销售用于音乐照明，但是 其核心算法具有临床潜力，因为它旨在通过刺激健康​​的大脑节律 在脑节律紊乱的临床人群中， 比如AD&MCI患者，我们认为这个技术可以有效恢复正常 对学习、记忆和认知很重要的大脑活动是该项目的主要成果。 IRB 批准的研究，1) 评估 SynchronyGamma 在独立生活中的可用性 设施，以及 2) 评估 SynchronyGamma 作为大脑刺激工具的可行性 研究 SynchronyGamma 对大脑活动和认知能力的纵向影响 对患有 MCI 或 AD 的老年人进行干预。 SynchronyGamma 有潜力通过创建一种机制来帮助与年龄相关的认知障碍 基于音乐的数字健康设备，通过音乐和灯光提供伽玛刺激。 神经退行性疾病是一个快速增长的公共卫生问题，仅 AD 就是其中之一 预计到 2050 年将影响 1,380 万美国人。AD 患者会经历渐进性认知障碍 下降，MCI 是该疾病的早期阶段。 经历多种痛点，包括记忆丧失、执行功能缺陷以及 MCI 阶段的早期干预可能会减少甚至逆转认知能力下降。 虽然 AD 的药物干预措施主要针对生物标志物，例如 β- 淀粉样蛋白 (Aβ) 斑块，这些策略在改善临床效果方面效果有限 因此，临床迫切需要开发针对 AD 和 MCI 的新疗法。 最近的发现将 Gamma 神经夹带与 Aβ 联系起来，为实现这一目标提供了令人兴奋的途径 我们的目标是验证 SynchronyGamma 作为一种非侵入性感官干预措施。 有效的基于音乐的疗法可以恢复耗尽的大脑活动，从而保留和 改善 AD 和 MCI 患者的记忆和认知。